British Society for Colposcopy & Cervical Pathology. 40th Anniversary Meeting. 18th - 20th April. The Sage, Gateshead.

Professor Henry Kitchener

Professor of Gynaecological Oncology
University of Manchester 1996 – to present

Chair of DH Advisory Committee for Cervical Screening
Immediate past Chair of Gynecological Cancer InterGroup
Trustee of BSCCP
Principal Investigator for the ARTISTIC and MAVARIC trials
Chair of the Sentinel Sites (HPV triage) Steering Group

Dr Janet McLelland

I trained in London and work as Consultant Dermatologist at the Royal
Victoria Infirmary, Newcastle upon Tyne.

I am Clinical Director for Plastic Surgery, Ophthalmology and Dermatology and am Assistant Honorary
Secretary of the British Association of Dermatologists.

I have been on the Committee of the British Society for the Study of Vulvo-vaginal Disease (BSSVD)  for several years and have organised the Annual meeting in Newcastle, held in March 2012.

Professor Peter Stern

Peter L Stern, PhD:
Peter L Stern is Head of the Immunology Group at Cancer Research UK‘s Paterson
Institute for Cancer Research at the University of Manchester. Professor Stern trained at University College, London, UK, obtaining his BSc and PhD. He has previously held research positions as staff scientist at the MRC Molecular Biology Laboratory, Cambridge, UK, European Molecular Biology Organization Fellow at the University of Uppsala, Sweden, Cancer Research Campaign Fellow and Junior Research Fellow at Linacre College, University of Oxford, UK, lecturer at the Medical School, University of Liverpool, UK, and Visiting Professor at the Free University of Amsterdam, The Netherlands. The theme of Professor Stern’s research has been the investigation of shared properties of developmental tissues and cancer cells with a view to identifying new targets for diagnosis, prognosis or therapy. This focus and application at the translational interface has enabled ideas to transfer successfully from the bench to the clinic. Examples include an MVA-based 5T4 oncofoetal antigen vaccine and a 5T4 antibody-based superantigen therapy, both of which are now in phase III clinical trials. In the field of HPV, Professor Stern’s activities have been directly related to the development of prophylactic and therapeutic treatments for patients with HPV-associated anogenital disease. This has included the design and delivery of clinical and laboratory analyses of numerous clinical trials of vaccines and other immunotherapies.